Checkpoint Surgical today announced the results of a study that called its handheld nerve monitor a safe and reliable alternative to existing technology for neural monitoring during surgery.
The retrospective study compared the use of the Cleveland, Ohio-based company’s Checkpoint nerve stimulator/locator to Medtronic’s nerve integrity monitor for vagal, recurrent and superior laryngeal nerve monitoring during thyroid and parathyroid surgeries. A total of 21 operated sides in 15 patients were included for analysis. Results of the study were published in the April 2019 issue of The Laryngoscope.
Dr. Gregory W. Randolph, director of the general and thyroid/parathyroid endocrine surgical divisions at Massachusetts Eye and Ear and a professor of otolaryngology at Harvard Medical School, led the study.
“The Checkpoint stimulator is a safe and reliable alternative to traditional laryngeal electromyography providing equivalent induced electromyography of the vocalis for neural monitoring during thyroid and parathyroid surgery,” the authors concluded.
“This is a very gratifying event for Checkpoint Surgical,” said president and CEO Len Cosentino in a news release. “We’ve always known from the reports of the surgeons who use our nerve stimulation technology that it provides safe, reliable and repeatable information for nerve assessment and protection during surgery. But the validation provided in this study is extremely meaningful to our clinical value proposition.”